Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in